LBT Innovations (ASX:LBT) - Managing Director & CEO, Brent Barnes
Managing Director & CEO, Brent Barnes
Source: LBT Innovations
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • LBT Innovations (LBT) has outlined a new board policy for its Non-Executive Directors
  • Under the new policy, directors will apply a salary sacrifice of 25 per cent to purchase new LBT shares
  • The policy will be in place until each Non-Executive Director has invested an amount equal to a full year’s gross directors’ fee
  • Thats said, the policy is still subject to shareholder approval
  • On market close for the weekend, LBT is up 7.14 per cent and is trading at 10.5 cents per share

LBT Innovations (LBT) has outlined a new board policy for its Non-Executive Directors.

Under the new policy, directors will apply a salary sacrifice of 25 per cent to purchase new LBT shares.

The LBT Board knows the importance of having directors invested in the future performance of the company, which is why the new board policy has been put in place.

LBT believes the new policy will represent an ongoing commitment from all Non-Executive Directors.

The policy will be in place until each Non-Executive Director has invested an amount equal to a full year’s gross directors’ fee.

However, the policy is subject to shareholder approval. If approved, new LBT shares will be issued within one month of the annual general meeting.

“This new board policy sets a commitment to ensure all directors invest in, and support, the future of LBT Innovations,” Chairman Kate Costello said.

“This is a positive indication of the long term potential the board see in the company and builds alignment between the LBT Board and feedback received from LBT shareholders,” he added.

On market close for the weekend, LBT is up 7.14 per cent and is trading at 10.5 cents per share.

LBT by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system